Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT), tells Proactive Investors their lead PD-L1 programme remains on track to deliver key pre-clinical milestones this year.
Smith says they're also making "excellent progress" with a second immuno-oncology research project, a LAG3 blockade, which can be combined with PD-L1 for improved efficacy.
Avacta, in its half-year results update, said its discovery programme continued to deliver a pipeline of binders to other important immuno-oncology targets for future partnering or development.
Meet 360 Blockchain Inc, Alterola Biotech, Inc, LGC Capital Ltd and Blowfish Technology at our event,New York, 18 April 2018.Register here >>